Neurocrine Biosciences, Inc NBIX Stock Price & News


Represents the company’s profit divided by the outstanding shares of its common stock. For the fiscal fourth quarter , NBIX’s total revenues increased 32.1% year-over-year to $412 million. There may be delays, omissions, or inaccuracies in the Information. As an investor, you want to buy stocks with the highest probability of success.

Where Does Neurocrine Biosciences, Inc. (NBIX) Stock Fall in the Drug Manufacturers – Specialty & Generic Field After It Is Up 3.05% This Week? – InvestorsObserver

Where Does Neurocrine Biosciences, Inc. (NBIX) Stock Fall in the Drug Manufacturers – Specialty & Generic Field After It Is Up 3.05% This Week?.

Posted: Thu, 30 Mar 2023 07:00:00 GMT [source]

In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company.

Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares

Vanguard Group Inc. now owns 9,000,963 shares of the company’s stock valued at $955,992,000 after buying an additional 96,489 shares during the period. Bellevue Group AG increased its holdings in Neurocrine Biosciences by 0.4% during the third quarter. Bellevue Group AG now owns 2,855,146 shares of the company’s stock valued at $303,245,000 after buying an additional 10,841 shares during the period. Bank of New York Mellon Corp increased its holdings in Neurocrine Biosciences by 2.2% during the third quarter.

Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Kevin C. Gorman has an approval rating of 97% among the company’s employees.

BMY: 1 Stock to Buy Today and Thank Yourself Later For –

BMY: 1 Stock to Buy Today and Thank Yourself Later For.

Posted: Thu, 10 Nov 2022 08:00:00 GMT [source] Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more. Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio. The trend in NBIX’s gross margin over the period from June 30, 2020, to December 31, 2022, is downwards, with a growth rate of -0.8%.

Financial Calendars

In 2022, NBIX’s revenue was $1.49 billion, an increase of 31.34% compared to the previous year’s $1.13 billion. Today, Culture Biosciences, a technology company that offers an easier, faster, and cheaper way to do biomanufacturing research and development (R&D), announced Series B financing of $80 million. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.

Intraday data delayed at least 15 minutes or per exchange requirements. EV / Sales ,77x EV / Sales ,83x Nbr of Employees Free-Float 97,3% More FinancialsCompanyNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.

Mammoth has now reached unicorn status in the industry with a valuation of more than $1 billion. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.

The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA. Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Neurocrine Biosciences by 1.1% during the third quarter.

The gross margin has fluctuated slightly, albeit downward, between 99.1% on June 30, 2020, and 98.4% on December 31, 2022. However, the net income significantly declined again in the subsequent quarters, falling to $364.7 million by the second quarter of 2022 and finishing at $154.5 million in the fourth quarter of 2022. Overall, NBIX’s net income has declined by 26% from the first quarter of 2020 to the last quarter of 2022. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

Zacks Mobile App

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. Neurocrine possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios. Real-time analyst ratings, insider transactions, earnings data, and more. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.


They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.

Net money flow is the value of uptick trades minus the value of downtick trades. While Neurocrine Biosciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… Market volume of $1.44 trillion by 2027 and an expected annual growth rate of 5.4%, the pharmaceutical industry could be a good destination for investors. Of this volume, the United States is expected to contribute a large portion of the revenues.

Neurocrine Biosciences Presents INGREZZA(R) (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

NBIX shares were trading at $101.02 per share on Friday afternoon, down $0.88 (-0.86%). Year-to-date, NBIX has declined -15.42%, versus a 8.97% rise in the benchmark S&P 500 index during the same period. There has been an overall decreasing trend in NBIX share prices, from its peak of $122.66 on November 11, 2022, to its bottom of $98.08 on March 10, 2023, before it recovered. Starting with the peak, the price declined by $4.64 over four weeks. After hitting the lowest point of $98.08, the share price rose by $5.18 over the following five weeks.

shares of neurocrine

what happens when you don t use your credit card – Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ stock is worth watching ahead of its first-quarter earnings next week. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company’s commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarbo…

Chief Research Officer notifies of intention to sell stock

This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. Neurocrine Biosciences has a short interest ratio (“days to cover”) of 3.4, which is generally considered an acceptable ratio of short interest to trading volume. 2.64% of the outstanding shares of Neurocrine Biosciences have been sold short.


A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

Insider Buying and Selling

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation’s leading newsletter advisors. When a company can find cost-effective ways to save money without compromising quality or credibility, it is news worth sharing. All values as of most recently reported quarter unless otherwise noted. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. Provide specific products and services to you, such as portfolio management or data aggregation. We’d like to share more about how we work and what drives our day-to-day business.

The largest positive contribution comes from its “Physical diseases” impact, which is driven by its “Valbenazine”, “Elagolix”, and “Opicapone” products. Neurocrine Biosciences does not have a long track record of dividend growth. Short interest in Neurocrine Biosciences has recently decreased by 7.61%, indicating that investor sentiment is improving significantly. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Measures how much net income or profit is generated as a percentage of revenue.

Futures: Stocks Near Bear Market Lows On Columbus Day – Investor’s Business Daily

Futures: Stocks Near Bear Market Lows On Columbus Day.

Posted: Mon, 10 Oct 2022 07:00:00 GMT [source]

According to 19 analysts, the average rating for NBIX stock is “Buy.” The 12-month stock price forecast is $123.11, which is an increase of 21.84% from the latest price. Between mid-December 2020 to mid-February 2021, NBIX stock rallied over 30% from $90 to $120… Intraday Data provided by FACTSET and subject to terms of use. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

  • Neurocrine Biosciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
  • Short interest in Neurocrine Biosciences has recently decreased by 7.61%, indicating that investor sentiment is improving significantly.
  • Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.
  • The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.

Momentum has been slightly decreasing since November 2022, with 27 being the peak and 36 being the lowest. Sentiment has seen fluctuation, with scores ranging from 35 to 67 since November of 2022, and Stability has had ratings between 41 and 49 during that time. The POWR Ratings for NBIX are most noteworthy for the Growth, Quality, and Value dimensions. Growth has consistently been amongst the highest ratings, with scores between 89 and 97 since November 2022. Quality has also been among the highest scores, with ratings around 93 to 96 through the dates provided. Revenue of NBIX has been steadily increasing since June 2020, when it was $100.56 million, to its current value of $148.87 million in December 2022.

Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 16 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” NBIX shares.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of NBIX stock can currently be purchased for approximately $101.04. “Prepare for Five Years of Famine”Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast. Earnings for Neurocrine Biosciences are expected to grow by 58.92% in the coming year, from $2.97 to $4.72 per share. Only 4.40% of the stock of Neurocrine Biosciences is held by insiders. Neurocrine Biosciences has received a 24.32% net impact score from Upright.

Leave a Reply

Your email address will not be published. Required fields are marked *